Minimal Residual Disease Market Report 2026

Minimal Residual Disease Market Overview

• Minimal Residual Disease market size has reached to $2.01 billion in 2025 • Expected to grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 12.2% • Growth Driver: Rising Cancer Prevalence Driving Growth In The Market • Market Trend: Innovations In Ultra-Sensitive MRD Testing Enhance Cancer Monitoring And Treatment Personalization • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Minimal Residual Disease Market?

Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse. The main types of detection targets for minimal residual disease are lymphoma, leukemia, solid tumors, and others. Lymphoma is a cancer originating in the lymphatic system, primarily targeting white blood cells known as lymphocytes. The various test techniques include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others and are used by several end-users, including banking, financial services, and insurance (BFSI), retail and e-commerce, hospitals, diagnostic laboratories, and research institutions.

What Is The Minimal Residual Disease Market Growth Forecast?

The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to rapid growth of ngs-based mrd testing, increasing demand for personalized oncology treatment, development of ultra-sensitive molecular assays, wider adoption of liquid biopsy mrd testing, rising investment in cancer diagnostics research. Major trends in the forecast period include adoption of precision medicine in mrd detection, integration of ai for enhanced sensitivity in mrd testing, expansion of cloud-based data management for mrd monitoring, iot-enabled connectivity in mrd diagnostic platforms, automation and digitalization in laboratory mrd analysis.

Global Minimal Residual Disease Market Segmentation

1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets 2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques 3) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions Subsegments: 1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma 2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia 3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer 4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas

What Is The Driver Of The Minimal Residual Disease Market?

The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to factors such as an aging population, increased exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. The rising cancer prevalence increases the demand for precise MRD testing to detect residual cancer cells, enabling early intervention and personalized treatment. This improves relapse prediction and enhances patient outcomes. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease industry.

Key Players In The Global Minimal Residual Disease Market

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., LabCorp, Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina Inc., Personalis Inc., Asuragen Inc., ARUP Laboratories Inc., Myriad Genetics Inc., Luminex Corporation, EntroGen Inc., 3B BlackBio Biotech India, Bioartis, PerkinElmer Inc.

Global Minimal Residual Disease Market Trends and Insights

Major companies operating in the minimal residual disease (MRD) market are focusing on developing advanced ultra-sensitive assays to enhance early detection and patient management. Ultra-sensitive assays are laboratory tests designed to detect circulating tumor DNA at extremely low frequencies with high accuracy, enabling earlier identification of cancer recurrence and improved treatment decisions. For instance, in April 2025, Natera, Inc., a US-based provider of cell-free DNA and genetic testing, launched the Signatera Genome MRD test featuring a personalized, tumor-informed assay built from a patient’s whole genome sequence and matched normal DNA. The test leverages multiplex polymerase chain reaction and next-generation sequencing technology to detect tumor DNA at frequencies as low as 1 part per million and below in research use. It has been clinically validated across multiple cancer types, including breast, colorectal, non-small cell lung, melanoma, and renal cell carcinoma. Signatera Genome identifies postsurgical patients at higher risk of recurrence, offers predictive clinical utility, supports both clinical and research applications, and has coverage from Medicare across a broad range of indications, enabling more precise and informed treatment strategies.

What Are Latest Mergers And Acquisitions In The Minimal Residual Disease Market?

In February 2024, Veracyte, Inc., a US-based cancer diagnostics company, acquired C2i Genomics, Inc. for $70 million. The acquisition integrates C2i Genomics' whole-genome minimal residual disease (MRD) expertise into Veracyte's diagnostic platform, strengthening its capacity to support patients across all stages of cancer care. C2i Genomics, Inc. is a US-based cancer intelligence company that provides a minimal residual disease (MRD) test.

Regional Outlook

North America was the largest region in the minimal residual disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Minimal Residual Disease Market?

The minimal residual disease market consists of revenues earned by entities by providing services such as cancer monitoring, relapse prediction, personalized treatment plans, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimal residual disease market also includes sales of clonality testing kits, MRD detection reagents, and MRD detection panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Minimal Residual Disease Market Report 2026?

The minimal residual disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.